

Bruce W Bode

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7180264/publications.pdf>

Version: 2024-02-01

52
papers

5,444
citations

109321

35
h-index

175258

52
g-index

52
all docs

52
docs citations

52
times ranked

3667
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced hypoglycaemia using liver-targeted insulin in individuals with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1762-1769.	4.4	3
2	Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 59-69.	4.4	11
3	Anti-interleukin-21 antibody and liraglutide for the preservation of β -cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 212-224.	11.4	85
4	Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 2154-2157.	8.6	16
5	Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial. <i>Diabetes Care</i> , 2019, 42, 1255-1262.	8.6	41
6	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , 2019, 42, 1147-1154.	8.6	249
7	Response to Comment on Russell-Jones et al. <i>Diabetes Care</i> 2017;40:943-950. Comment on Bowering et al. <i>Diabetes Care</i> 2017;40:951-957. <i>Diabetes Care</i> , 2018, 41, e29-e30.	8.6	2
8	Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 145-151.	2.2	42
9	Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 639-647.	4.4	36
10	Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. <i>Diabetes Care</i> , 2018, 41, 1970-1980.	8.6	170
11	Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1). <i>Diabetes</i> , 2018, 67, 212-OR.	0.6	4
12	Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 155-163.	4.4	481
13	An Expert Opinion on Advanced Insulin Pump Use in Youth with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 145-154.	4.4	9
14	Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. <i>Diabetes Care</i> , 2017, 40, 951-957.	8.6	102
15	Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1). <i>Diabetes Care</i> , 2017, 40, 943-950.	8.6	148
16	American Association Of Clinical Endocrinologists And American College Of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement. <i>Endocrine Practice</i> , 2016, 22, 231-262.	2.1	97
17	The Emerging Role Of Adjunctive Noninsulin Antihyperglycemic Therapy In The Management Of Type 1 Diabetes. <i>Endocrine Practice</i> , 2016, 22, 220-230.	2.1	46
18	Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. <i>Diabetes Care</i> , 2016, 39, 1702-1710.	8.6	200

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 543-552.	2.6	64
20	Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial. <i>Diabetes Care</i> , 2015, 38, 2266-2273.	8.6	74
21	Hypoglycemia Reduction and Changes in Hemoglobin A1c in the ASPIRE In-Home Study. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 542-547.	4.4	49
22	Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1181-1188.	8.6	194
23	Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. <i>BMC Endocrine Disorders</i> , 2014, 14, 37.	2.2	80
24	Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force. <i>Endocrine Practice</i> , 2014, 20, 463-489.	2.1	140
25	Effect of Sitagliptin on Post-Prandial Glucagon and GLP-1 Levels in Patients With Type 1 Diabetes: Investigator-Initiated, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Endocrine Practice</i> , 2013, 19, 19-28.	2.1	83
26	Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized Trial. <i>Hospital Practice (1995)</i> , 2013, 41, 72-84.	1.0	210
27	An overview of the pharmacokinetics, efficacy and safety of liraglutide. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, 27-42.	2.8	64
28	The V-Go Insulin Delivery Device Used In Clinical Practice: Patient Perception and Retrospective Analysis of Glycemic Control. <i>Endocrine Practice</i> , 2012, 18, 660-667.	2.1	24
29	Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes ≥ 65 and < 65 Years of Age: A Pooled Analysis from Phase III Studies. <i>American Journal of Geriatric Pharmacotherapy</i> , 2011, 9, 423-433.	3.0	51
30	Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues— aspart, lispro, and glulisine. <i>Endocrine Practice</i> , 2011, 17, 271-280.	2.1	42
31	A 16-Week Open-Label, Multicenter Pilot Study Assessing Insulin Pump Therapy in Patients with Type 2 Diabetes Suboptimally Controlled with Multiple Daily Injections. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 887-893.	2.2	24
32	Liraglutide: a review of the first once-daily GLP-1 receptor agonist. <i>American Journal of Managed Care</i> , 2011, 17, S59-70.	1.1	12
33	Insulin Pump Therapy in Patients with Type 2 Diabetes Safely Improved Glycemic Control Using a Simple Insulin Dosing Regimen. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, 627-633.	4.4	54
34	Insulin Pump Use in Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, S-17-S-21.	4.4	45
35	Individualizing Care for the Many. <i>The Diabetes Educator</i> , 2010, 36, 4S-19S.	2.5	29
36	Defining the Importance of Daily Glycemic Control and Implications for Type 2 Diabetes Management. <i>Postgraduate Medicine</i> , 2009, 121, 82-93.	2.0	11

#	ARTICLE	IF	CITATIONS
37	Incretin-Based Therapies: Review of the Outpatient Literature with Implications for Use in the Hospital and After Discharge. <i>Hospital Practice</i> (1995), 2009, 37, 7-21.	1.0	2
38	Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. <i>Lancet, The</i> , 2009, 373, 473-481.	13.7	935
39	Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: Insulin pump therapy versus multiple daily injections. <i>Clinical Therapeutics</i> , 2007, 29, S135-S144.	2.5	33
40	Demonstrations and Discussions of Continuous Glucose Monitors. <i>Diabetes Technology and Therapeutics</i> , 2005, 7, 805-808.	4.4	1
41	Analysis: The Suboptimal Roadmap to the Intensive Therapy Target. <i>Diabetes Technology and Therapeutics</i> , 2004, 6, 17-19.	4.4	3
42	Intravenous Insulin Infusion Therapy: Indications, Methods, and Transition to Subcutaneous Insulin Therapy. <i>Endocrine Practice</i> , 2004, 10, 71-80.	2.1	144
43	Alarms Based on Real-Time Sensor Glucose Values Alert Patients to Hypo- and Hyperglycemia: The Guardian Continuous Monitoring System. <i>Diabetes Technology and Therapeutics</i> , 2004, 6, 105-113.	4.4	166
44	Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes: A randomized, parallel-group, 24-week study. <i>Diabetes Care</i> , 2003, 26, 2598-2603.	8.6	235
45	Insulin pump therapy in the 21st century. <i>Postgraduate Medicine</i> , 2002, 111, 69-77.	2.0	90
46	Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin Infusion: A randomized study in type 1 diabetes. <i>Diabetes Care</i> , 2002, 25, 439-444.	8.6	138
47	Diabetes management in the new millennium using insulin pump therapy. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, S14-S20.	4.0	128
48	Intensive Insulin Therapy and Insulin Pumps. <i>Postgraduate Medicine</i> , 2002, 112, 017-021.	2.0	3
49	What's ahead in glucose monitoring?. <i>Postgraduate Medicine</i> , 2001, 109, 41-49.	2.0	25
50	Clinical Utility of the Continuous Glucose Monitoring System. <i>Diabetes Technology and Therapeutics</i> , 2000, 2, 35-41.	4.4	56
51	Performance Evaluation of the MiniMedÂ® Continuous Glucose Monitoring System During Patient Home Use. <i>Diabetes Technology and Therapeutics</i> , 2000, 2, 49-56.	4.4	268
52	Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. <i>Diabetes Research and Clinical Practice</i> , 1999, 46, 183-190.	2.8	225